Literature DB >> 16880827

Hyperforin prevents beta-amyloid neurotoxicity and spatial memory impairments by disaggregation of Alzheimer's amyloid-beta-deposits.

M C Dinamarca1, W Cerpa, J Garrido, J L Hancke, N C Inestrosa.   

Abstract

The major protein constituent of amyloid deposits in Alzheimer's disease (AD) is the amyloid beta-peptide (Abeta). In the present work, we have determined the effect of hyperforin an acylphloroglucinol compound isolated from Hypericum perforatum (St John's Wort), on Abeta-induced spatial memory impairments and on Abeta neurotoxicity. We report here that hyperforin: (1) decreases amyloid deposit formation in rats injected with amyloid fibrils in the hippocampus; (2) decreases the neuropathological changes and behavioral impairments in a rat model of amyloidosis; (3) prevents Abeta-induced neurotoxicity in hippocampal neurons both from amyloid fibrils and Abeta oligomers, avoiding the increase in reactive oxidative species associated with amyloid toxicity. Both effects could be explained by the capacity of hyperforin to disaggregate amyloid deposits in a dose and time-dependent manner and to decrease Abeta aggregation and amyloid formation. Altogether these evidences suggest that hyperforin may be useful to decrease amyloid burden and toxicity in AD patients, and may be a putative therapeutic agent to fight the disease.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16880827     DOI: 10.1038/sj.mp.4001866

Source DB:  PubMed          Journal:  Mol Psychiatry        ISSN: 1359-4184            Impact factor:   15.992


  31 in total

1.  Profiling of hypothalamic and hippocampal gene expression in chronically stressed rats treated with St. John's wort extract (STW 3-VI) and fluoxetine.

Authors:  Peggy Jungke; Gigi Ostrow; Jian-Liang Li; Sharon Norton; Karen Nieber; Olaf Kelber; Veronika Butterweck
Journal:  Psychopharmacology (Berl)       Date:  2010-10-06       Impact factor: 4.530

Review 2.  Neurotrophic natural products: chemistry and biology.

Authors:  Jing Xu; Michelle H Lacoske; Emmanuel A Theodorakis
Journal:  Angew Chem Int Ed Engl       Date:  2013-12-18       Impact factor: 15.336

3.  Up-regulation of P-glycoprotein reduces intracellular accumulation of beta amyloid: investigation of P-glycoprotein as a novel therapeutic target for Alzheimer's disease.

Authors:  Alaa H Abuznait; Courtney Cain; Drury Ingram; David Burk; Amal Kaddoumi
Journal:  J Pharm Pharmacol       Date:  2011-06-11       Impact factor: 3.765

4.  Amyloid-beta-Acetylcholinesterase complexes potentiate neurodegenerative changes induced by the Abeta peptide. Implications for the pathogenesis of Alzheimer's disease.

Authors:  Margarita C Dinamarca; Juan P Sagal; Rodrigo A Quintanilla; Juan A Godoy; Macarena S Arrázola; Nibaldo C Inestrosa
Journal:  Mol Neurodegener       Date:  2010-01-18       Impact factor: 14.195

5.  Derivatives of Piperazines as Potential Therapeutic Agents for Alzheimer's Disease.

Authors:  Elena Popugaeva; Daria Chernyuk; Hua Zhang; Tatyana Y Postnikova; Karina Pats; Elena Fedorova; Vladimir Poroikov; Aleksey V Zaitsev; Ilya Bezprozvanny
Journal:  Mol Pharmacol       Date:  2019-01-29       Impact factor: 4.436

6.  Apolipoprotein E3 (ApoE3) but not ApoE4 protects against synaptic loss through increased expression of protein kinase C epsilon.

Authors:  Abhik Sen; Daniel L Alkon; Thomas J Nelson
Journal:  J Biol Chem       Date:  2012-03-17       Impact factor: 5.157

Review 7.  Dysregulation of neuronal calcium homeostasis in Alzheimer's disease - A therapeutic opportunity?

Authors:  Elena Popugaeva; Ekaterina Pchitskaya; Ilya Bezprozvanny
Journal:  Biochem Biophys Res Commun       Date:  2016-09-15       Impact factor: 3.575

8.  Reversal of Calcium Dysregulation as Potential Approach for Treating Alzheimer's Disease.

Authors:  Elena Popugaeva; Daria Chernyuk; Ilya Bezprozvanny
Journal:  Curr Alzheimer Res       Date:  2020       Impact factor: 3.498

9.  Complementary and alternative medicine use for treatment and prevention of late-life mood and cognitive disorders.

Authors:  Helen Lavretsky
Journal:  Aging health       Date:  2009-02-01

10.  Antidepressants are a rational complementary therapy for the treatment of Alzheimer's disease.

Authors:  Marwa Aboukhatwa; Laura Dosanjh; Yuan Luo
Journal:  Mol Neurodegener       Date:  2010-03-12       Impact factor: 14.195

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.